11th European Post-Chicago Melanoma/Skin Cancer Meeting

Results and Interpretations of ASCO Presentations 2021: Interdisciplinary Global Conference on News in Melanoma/Skin Cancer

JULY 8th–9th, 2021

www.postchicago2021.org
Transforming patients' lives through science™

We are in the business of breakthroughs—the kind that transform patients' lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we'll never give up our search for more hope, for more people, around the world.

Visit bms.com to see how we're bringing a human touch to everything we do.

We're proud to support the 11th European Post Chicago Melanoma/Skin Cancer Meeting
CONTENT

» WELCOME MESSAGE 01

» PROGRAM AT A GLANCE 02

» PROGRAM 04
  Thursday, July 8th 04
  Friday, July 9th 07

» CONGRESS FACULTY 10

» FLOOR PLAN 13

» SATELLITE SYMPOSIA OVERVIEW 13

» GENERAL INFORMATION 17

» SPONSORS 18
Dear colleagues and friends,

The first Post-Chicago Meeting on Melanoma/Skin Cancer took place 2011. In 2019, the meeting has attracted more than 700 participants from 34 countries. Last year the Post-Chicago Meeting meeting was organized successfully as a virtual meeting and attracted more than 1,000 participants. The interactive congress offers a comprehensive overview on all new developments in melanoma diagnostics and therapy and a direct communication with the world’s leading experts in these fields.

The aim of the Interdisciplinary Global Conference on News in Melanoma/Skin Cancer is to grant a deep overall insight into the development of new drugs for melanoma and other cutaneous malignancies. The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant.

International key opinion leaders on melanoma will be invited to give an overview throughout specified presentations, to present latest clinical trial results, and to discuss on exciting new drugs with the audience. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities of Germany.

Please join us for this event and submit your own studies and case presentations as free communications and as posters.

We look forward to welcoming you ONLINE in July 2021!

Axel Hauschild, MD
Congress President

Claus Garbe, MD
Congress President
8:00 - Opening of the conference

9:00 - SYMPOSIUM I
   My personal highlights at ASCO 2021

10:00 - SATELLITE SYMPOSIUM I

11:00 - BREAK

12:00 - SATELLITE SYMPOSIUM II

13:00 - SYMPOSIUM II
   Gene expression profiling

14:00 - BREAK

15:00 - SATELLITE SYMPOSIUM III

16:00 - SYMPOSIUM III
   Are triplets for metastatic melanoma dead?

17:00 - KEY NOTE LECTURE

18:00 - SYMPOSIUM IV
   Biomarkers for Melanoma

19:00 - SPECIAL LECTURE

THURSDAY, JULY 8TH
FRIDAY, JULY 9TH

8:00 | SYMPOSIUM V
     | New treatment opportunities for metastatic ocular melanoma

9:00 | SATELLITE SYMPOSIUM IV

10:00 | KEY NOTE LECTURE

11:00 | SATELLITE SYMPOSIUM V

12:00 | BREAK

13:00 | SYMPOSIUM VI
     | Squamous Cell Carcinoma

14:00 | BREAK

15:00 | SATELLITE SYMPOSIUM VI

16:00 | SATELLITE SYMPOSIUM VII

17:00 | BREAK

18:00 | SYMPOSIUM VIII
     | Merkel Cell Carcinoma

19:00 | SYMPOSIUM IX
     | Difficult to treat skin cancer patients: Frequently asked questions in dermatoncology
     | CLOSING REMARKS
**THURSDAY, JULY 8TH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>OPENING OF THE CONFERENCE</td>
<td>CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY</td>
</tr>
<tr>
<td>08:10–09:30</td>
<td>SYMPOSIUM I</td>
<td>My personal highlights at ASCO 2021</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHAIRPERSONS: PETER MOHR, BUXTEHUDE, GERMANY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CELESTE LEBBÉ, PARIS, FRANCE</td>
</tr>
<tr>
<td></td>
<td>08:10–08:40</td>
<td>... in melanoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Grant McArthur, Melbourne, Australia</td>
</tr>
<tr>
<td></td>
<td>08:50–09:20</td>
<td>... in non-melanoma skin cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Celeste Lebbé, Paris, France</td>
</tr>
<tr>
<td>09:30–10:30</td>
<td>SATELLITE SYMPOSIUM I</td>
<td><em>(see page 13)</em></td>
</tr>
<tr>
<td>10:30–11:00</td>
<td>KEY NOTE LECTURE</td>
<td>CHAIRPERSON: ROLAND KAUFMANN, FRANKFURT, GERMANY</td>
</tr>
<tr>
<td></td>
<td>10:30–11:00</td>
<td>Is melanoma surgery dead?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alexander Eggermont, Utrecht, The Netherlands</td>
</tr>
<tr>
<td>11:00–11:30</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>11:30–13:00</td>
<td>SATELLITE SYMPOSIUM II</td>
<td><em>(see page 13)</em></td>
</tr>
</tbody>
</table>
13:00–14:00 SYMPOSIUM II
Gene expression profiling
CHAIRPERSONS: BASTIAN SCHILLING, WUERZBURG, GERMANY
PAOLO ASCIERTO, NAPLES, ITALY
13:00–13:17 Principles of gene expression profiling
   **Olivier Michielin, Lausanne, Switzerland**
13:20–13:37 Gene expression profiling tests: Which test is the best?
   **Vernon Sondak, Tampa, USA**
13:40–13:57 Gene expression profiling in clinical trials
   **Dirk Schadendorf, Essen, Germany**

14:00–14:30 COFFEE BREAK

14:30–16:00 SATELLITE SYMPOSIUM III
(see page 14)

16:00–16:45 SYMPOSIUM III
Are triplets for metastatic melanoma dead?
CHAIRPERSONS: ANA ARANCE, BARCELONA, SPAIN
   JEAN JACQUES GROB, MARSEILLE, FRANCE
16:00–16:15 Yes
   **James Larkin, London, United Kingdom**
16:15–16:30 No
   **Ralf Gutzmer, Minden, Germany**
16:30–16:45 Panel discussion
   **Ana Arance, Jean Jacques Grob, Ralf Gutzmer, James Larkin**

16:45–17:00 BREAK
17:00–17:30  KEY NOTE LECTURE
CHAIRPERSON: LUCIE HEINZERLING, MUNICH, GERMANY
17:00–17:30  Adoptive T-cell transfer: Ready for prime time?
Jeffrey Weber, New York, USA

17:30–18:30  SYMPOSIUM IV
Biomarkers for Melanoma
CHAIRPERSONS: STEPHAN GRABBE, MAINZ, GERMANY
BRIGITTE DRENO, NANTES, FRANCE
17:30–17:45  Circulating tumor DNA for treatment monitoring
Christoffer Gebhardt, Hamburg, Germany
17:45–18:00  Tumor mutational burden for treatment decisions
Caroline Robert, Paris, France
18:00–18:15  PD-L1 and LAG-3 testing for treatment decisions
Christoph Höller, Vienna, Austria
18:15–18:30  Panel discussion
Christoffer Gebhardt, Christoph Höller, Caroline Robert

18:30–19:15  SPECIAL LECTURE with panel disussion
CHAIRPERSONS: DIRK SCHADENDORF, ESSEN, GERMANY
ALEXANDER VAN AKKOOI, AMSTERDAM, THE NETHERLANDS
18:30–19:00  Future roll of neoadjuvant treatment
Christian Blank, Amsterdam, The Netherlands
19:00–19:15  Panel discussion
Alexander van Akkooi, Christian Blank, Dirk Schadendorf
08:00–09:00 SYMPOSIUM V
New treatment opportunities for metastatic ocular melanoma
CME symposium supported by an unconditional educational grant from Immunocore

CHAIRPERSONS: PAUL LORIGAN, MANCHESTER, UNITED KINGDOM
AXEL HAUSCHILD, KIEL, GERMANY

08.00–08.10 Conventional systemic and regional chemotherapies for metastatic ocular melanoma
Selma Ugurel, Essen, Germany

08.10–08.20 Immune checkpoint inhibition: Efficacy, toxicity and limitations
Paul Nathan, London, United Kingdom

08.20–08.40 Tebentafusp (IMC gp100) studies from AACR and ASCO 2021
Jessica Hassel, Heidelberg, Germany

08.40–09.00 Panel Discussion
Paul Lorigan, Axel Hauschild, Selma Ugurel, Paul Nathan and Jessica Hassel

09:00–09:30 SATELLITE SYMPOSIUM IV
(see page 15)

09:30–10:30 KEY NOTE LECTURES
CHAIRPERSONS: CLAUS GARBE, TUEBINGEN, GERMANY
AXEL HAUSCHILD, KIEL, GERMANY

09:30–10:00 My visions on NMSC treatment 2025
Paul Nghiem, Seattle, USA

10:00–10:30 My visions on melanoma treatment 2025
Georgina Long, Sydney, Australia

10:30–12:00 SATELLITE SYMPOSIUM V
(see page 15)
12:00–12:30  BREAK

12:30–13:15  SYMPOSIUM VI  
Squamous Cell Carcinoma  
CHAIRPERSONS: ULRIKE LEITER, TUEBINGEN, GERMANY  
GIOVANNI PELLACANI, MODENA, ITALY  
12:30–12:42  Update on chemotherapy and EGFR-Inhibitors  
Lidija Kandolf-Sekulovic, Belgrade, Serbia  
12:45–12:57  Update on immunotherapies  
Reinhard Dummer, Zurich, Switzerland  
13:00–13:12  Update on adjuvant and neoadjuvant treatment  
Iris Zalaudek, Trieste, Italy

13:15–14:00  SYMPOSIUM VII  
Basal Cell Carcinoma  
CHAIRPERSONS: PETR ARENBERGER, PRAGUE, CZECH REPUBLIC  
THOMAS EIGENTLER, TUEBINGEN, GERMANY  
13:15–13:27  Update on hedgehog inhibitors  
Nicole Basset-Seguin, Paris, France  
13:30–13:42  Update on immunotherapies  
Ketty Peris, Rome, Italy  
13:45–13:57  Update on neoadjuvant treatment  
Celeste Lebbé, Paris, France

14:00–14:30  BREAK

14:30–16:00  SATELLITE SYMPOSIUM VI  
(see page 16)

16:00–17:00  SATELLITE SYMPOSIUM VII  
(see page 16)
17:00–17:15  BREAK

17:15–18:00  SYMPOSIUM VIII
Merkel Cell Carcinoma
CHAIRPERSONS: ERIKA RICHTIG, GRAZ, AUSTRIA
CELESTE LEBBÉ, PARIS, FRANCE
17:15–17:27  Update on adjuvant and neoadjuvant treatment
Jürgen Becker, Essen, Germany
17:30–17:42  Update on immunotherapies
Paolo Ascierto, Naples, Italy
17:45–17:57  CAR-T cells for cutaneous malignancies?
Carola Berking, Erlangen, Germany

18:00–19:00  SYMPOSIUM IX
Difficult to treat skin cancer patients: Frequently asked questions
in dermatooncology
CHAIRPERSONS: FRIEDEGUND MEIER, DRESDEN, GERMANY
JEAN JACQUES GROB, MARSEILLE, FRANCE
18:00–18:12  How to treat organ transplant patients?
Selma Ugurel, Essen, Germany
18:15–18:27  How to treat symptomatic brain mets?
Hussein Tawbi, Houston, USA
18:30–18:42  How to treat metastatic uveal melanoma?
Paul Nathan, London, United Kingdom
18:45–18:57  How to treat mucosal melanoma?
Paul Lorigan, Manchester, United Kingdom

19:00  CLOSING REMARKS
Claus Garbe, Tübingen Germany
CONGRESS FACULTY

A

Alexander van Akkooi, MD
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek
Amsterdam, The Netherlands
Email: a.v.akkooi@nki.nl

Ana Arance, MD
Hospital Clinic of Barcelona Carrer de Villarroel
170 Barcelona, Spain

Petr Arenberger, MD
Department of Dermatology
Charles University
3rd School of Medicine
Prague, Czech Republic
Email: avemedica@email.cz

Paolo Ascierto, MD
Melanoma, Cancer Immunotherapy and Innovative Therapy Unit National Cancer Institute
Naples, Italy
Email: paolo.ascierto@gmail.com

B

Nicole Basset-Seguin, MD
Hospital Saint Louis, Paris, France

Jürgen Becker, MD
Department of Dermatology
University Hospital Essen
Hufelandstr. 55
Essen, Germany

Carola Berking, MD
Department of Dermatology University Hospital of Erlangen
Erlangen, Germany

Christian Blank, MD
The Netherlands Cancer Institute
Amsterdam, The Netherlands
Email: c.blank@nki.nl

D

Brigitte Dreno, MD
Faculty of Medicine Nantes France
Nantes, France

Reinhard Dummer, MD
Department of Dermatology University of Zurich
Zurich, Switzerland
Email: reinhard.dummer@usz.ch

E

Alexander M.M. Eggermont, MD
University of Utrecht
Utrecht, The Netherlands

Thomas Eigentler, MD
Department of Dermatology
Eberhard Karls University
Tuebingen, Germany
Email: thomas.eigentler@med.uni-tuebingen.de

G

Claus Garbe, MD
Department of Dermatology
Eberhard Karls University
Tuebingen, Germany
Email: claus.garbe@med.uni-tuebingen.de

Christoffer Gebhardt, MD
Skin Cancer Center
University Hospital Hamburg-Eppendorf
Hamburg, Germany
Email: ch.gebhardt@uke.de

Stephan Grabbe, MD
Department of Dermatology
Johannes Gutenberg University
Mainz, Germany

Jean Jacques Grob, MD
Service de Dermatology and Cancer Research – Hospital de la Timone
Marseille, France
Email: jean-jacques.grob@ap-hm.fr

Ralf Gutzmer, MD
Mühlenkreisklinikum
Dermato-Oncology
Minden, Germany
Email: dermatologie-minden@muehlenkreiskliniken.de
Axel Hauschild, MD
Skin Cancer Center
University of Kiel
Kiel, Germany
Email: ahauschild@dermatology.uni-kiel.de

Lucie Heinzerling, MD
Department of Dermatology University
Hospital of Munich
Munich, Germany

Christoph Höller, MD
Department of Dermatology
Medical University of Vienna
Vienna, Austria
Email: christoph.hoeller@meduniwien.ac.at

Lidija Kandolf-Sekulovic, MD
Department of Dermatology Military Medical Academy
Belgrade, Serbia
Email: lkandolfsekulovic@gmail.com

Roland Kaufmann, MD
Department of Dermatology
Clinical Center J. W. Goethe University
Frankfurt am Main, Germany
Email: kaufmann@em.uni-frankfurt.de

James Larkin, MD
Consultant Medical Oncologist
The Royal Marsden Hospital
London, United Kingdom
Email: james.larkin@rmh.nhs.uk

Celeste Lebbé, MD
Department of Dermatology Hospital Saint-Louis
Paris, France
Email: celeste.lebbe@aphp.fr

Ulrike Leiter, MD
Department of Dermatology
Eberhard Karls University
Tuebingen, Germany
Email: ulrike.leiter@med.uni-tuebingen.de

Georgina Long, MD
Melanoma Institute Australia
The University of Sydney
Sydney, Australia
Email: georgina.long@sydney.edu.au

Paul Lorigan, MD
University of Manchester Christie NHS Foundation Trust
Manchester, United Kingdom
Email: paul.lorigan@christie.nhs.uk

Grant McArthur, MD
Peter MacCallum Cancer Centre
Melbourne, Australia
Email: grant.mcardur@petermac.org

Friedegund Meier, MD
Skin Cancer Center University Clinic Dresden
Dresden, Germany

Olivier Michielin, MD
Department of Oncology
Swiss Institute of Bioinformatics
Lausanne, Switzerland
Email: Olivier.Michielin@chuv.ch

Peter Mohr, MD
Center of Dermatology
Elbe Klinikum Buxtehude
Buxtehude, Germany
Email: peter.mohr@elbekliniken.de

Paul Nathan, MD
Mount Vernon Cancer Centre Rickmansworth
Road Northwood, United Kingdom
Email: p.nathan@nhs.net

Paul Nghiem, MD
University of Washington Fred Hutchinson Cancer
Seattle, USA
THURSDAY, JULY 8TH

09:30–10:30  SATELLITE SYMPOSIUM I

Pierre Fabre

CHAIRS: AXEL HAUSCHILD, KIEL, GERMANY
 GEORGINA LONG, SYDNEY, AUSTRALIA

How to achieve long-term outcomes for patients with advanced BRAF-mutant melanoma?

09:30–09:35  Welcome and introductions
  Axel Hauschild, Kiel, Germany

09:35–09:45  Our current understanding of the targeted therapy landscape in advanced BRAF-mutant melanoma (live session)
  Axel Hauschild, Kiel, Germany

09:45–10:00  Clinical experience in achieving long-term outcomes for patients with advanced BRAF-mutant melanoma (case reviews)
  Mario Mandalà, Perugia, Italy and Eva Muñoz, Barcelona, Spain

10:00–10:10  Clinical perspectives on patient outcomes (live session)
  Georgina Long, Sydney, Australia

10:10–10:25  Panel discussion: Your questions answered (live session with audience Q&A)
  All faculty. Moderated by Georgina Long, Sydney, Australia and Axel Hauschild, Kiel, Germany

10:25–10:30  Closing remarks
  Georgina Long, Sydney, Australia

11:30–13:00  SATELLITE SYMPOSIUM II

Bristol Myers Squibb

CHAIR: DIRK SCHADENDORF, ESSEN, GERMANY

Leading title: The melanoma IO-treatment continuum: latest achievements and persistent challenges

11:30–11:35  Welcome and Introduction
  Dirk Schadendorf, Essen, Germany

11:35–12:00  Long term outcome and open questions under IO-combination therapy
  James Larkin, London, United Kingdom

12:00–12:05  Live Panel Discussion

12:05–12:20  What can we expect from new combinations in the future?
  Peter Mohr, Buxtehude, Germany

12:20–12:25  Live Panel Discussion

12:25–12:45  The (Un)Known about therapeutic sequencing
  Dirk Schadendorf, Essen, Germany

12:45–12:50  Live Panel Discussion

12:50–13:00  Closing Remarks
14:30–16:00  SATELLITE SYMPOSIUM III

MSD

Transforming Patient Care in Melanoma

CHAIR: AXEL HAUSCHILD, KIEL, GERMANY

14:30–14:35  Welcome and Introduction
Axel Hauschild, Kiel, Germany

Adjuvant treatment of high-risk melanoma

14:35–14:50  Evolving landscape of adjuvant treatment or high-risk melanoma
Olivier Michielin, Lausanne, Switzerland

14:50–15:10  Translating data into clinical practice
Merrick Ross, Houston, USA

Advanced Melanoma

Christoph Höller, Vienna, Austria

15:25–15:45  Combining data with clinical experience to optimize patient outcome with advanced melanoma
Hussein Tawbi, Houston, USA

15:45–16:00  Q&A / Panel discussion
All faculty

Closing remarks
Axel Hauschild, Kiel, Germany
FRIDAY, JULY 9TH

09:00–09:30  SATELLITE SYMPOSIUM IV

Philogen
Daromun: a new intralesional therapy for skin cancers
CHAIR: AXEL HAUSCHILD, KIEL, GERMANY
09:00–09:12  Applications in melanoma
Piotr Rutkowski, Warsaw, Polen
09:12–09:24  Applications in Non-melanoma skin cancers
Lukas Flatz, St. Gallen, Switzerland
09:24–09:30  Q&A and Panel Discussion
All faculty

10:30–12:00  SATELLITE SYMPOSIUM V

Novartis
Evolving Considerations for Patient Management in Melanoma
CHAIR: AXEL HAUSCHILD, KIEL, GERMANY
10:30–10:35  Welcome From the Chair
Axel Hauschild, Kiel, Germany
10:35–10:40  Current State of the Melanoma Treatment Landscape
10:40–10:50  Clinical Insights, Discussion and Q&A
Axel Hauschild, Peter Mohr, Dirk Schadendorf
10:50–11:05  Strategies for Effective Adverse Event Management
Victoria Atkinson
11:05–11:15  Clinical Insights, Discussion and Q&A
Axel Hauschild, Peter Mohr, Dirk Schadendorf
11:15–11:35  Considerations for Patient Management in the Time of COVID-19
Dirk Schadendorf, Katharina Kaminski (patient advocate)
11:35–11:45  Clinical Insights, Discussion and Q&A
Axel Hauschild, Peter Mohr, Dirk Schadendorf
11:45–12:00  General Discussion and Q&A
Axel Hauschild, Peter Mohr, Dirk Schadendorf
14:30–16:00  SATELLITE SYMPOSIUM VI

Sanofi Genzyme

14:30–14:35  Welcome and introduction
Irish Zalaudek, Trieste, Italy

14:35–14:55  Why are NMSCs sensitive to immunotherapy?
Molecular and immunologic considerations
Reinhard Dummer, Zurich, Switzerland

14:55–15:15  Application of immunotherapy in clinical practice
for advanced CSCC management
Michael R. Migden, Houston, USA

15:15–15:35  Immunotherapy for advanced BCC:
What are the clinical implications?
Jean-Jacques Grob, Marseille, France

15:35–15:50  Difficult-to-treat NMSC patients – Interactive case discussion
Irish Zalaudek, Trieste, Italy

15:50–16:00  Ask the faculty and concluding remarks
All faculty

16:00–17:00  SATELLITE SYMPOSIUM VII

Kyowa Kirin

Cutaneous T-cell lymphoma: 1 year experience
with anti-CCR4 antibody mogamulizumab
CHAIR: PROF. DR. CLAUS-DETLEV KLEMKE, KARLSRUHE, GERMANY

16:00–16:05  Welcome and introduction
Prof. Dr. Claus-Detlev Klemke, Karlsruhe, Germany

16:05–16:15  MAJORIC post-hoc analysis
Prof. Dr. Claus-Detlev Klemke, Karlsruhe, Germany

16:15–16:30  Long-term remission in patients with Sézary syndrome
under mogamulizumab
Dr. Stephan A. Braun, Münster, Germany

16:30–16:50  Therapy of early mycosis fungoides with TSEB and mogamulizumab
in a multidisciplinary setting
Prof. Dr. Claudia Pföhler, Homburg, Germany
Dr. Khaled Elsayad, Münster, Germany

16:50–17:00  Discussion and Q&A
Cancellation Policy
Cancellations must be received in writing by May 27th, 2021. No refunds will be granted after that date. To cancel a registration, please send an email to info@medconcept.org and include “European Post-Chicago Meeting 2021 Cancellation” in the subject line. A processing fee of 30 Euro will be deducted from each cancelled registration.
Substitutions (new ticket holder must come from the same institution) are possible and must be received in writing by June 24th, 2021. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org and include “European Post-Chicago Meeting 2021 Substitution” in the subject line.
The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

CME Credits
An application for CME accreditation has been made. The 11th European Post-Chicago Melanoma/Skin Cancer Meeting has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) with 10 European CME credits (ECMEC).

Congress Date
July 8th–July 9th, 2021

Congress Organization
MEDCONCEPT
Gesellschaft für medizinische Projekte mbH
Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany
info@medconcept.org · www.medconcept.org · Phone +49 (0)3342 42689-30 · Fax +49 (0)3342 42689-40

Language and Translation
The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration
Please visit the congress website www.postchicago2021.org for online registration or fill out the registration form on the last page of the program.

Registration Fees

<table>
<thead>
<tr>
<th></th>
<th>Early Bird till April 30th</th>
<th>Regular Fee from May 1st till July 4th</th>
<th>On site from July 5th</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virtual Ticket</td>
<td>200 Euro</td>
<td>200 Euro</td>
<td>200 Euro</td>
</tr>
<tr>
<td>Students/Nurses Ticket*</td>
<td>100 Euro</td>
<td>100 Euro</td>
<td>100 Euro</td>
</tr>
<tr>
<td>Eastern European Countries*</td>
<td>100 Euro</td>
<td>100 Euro</td>
<td>100 Euro</td>
</tr>
<tr>
<td>Patient Advocates*</td>
<td>0 Euro</td>
<td>0 Euro</td>
<td>0 Euro</td>
</tr>
</tbody>
</table>

*Please forward appropriate documentary evidence via mail, email or fax to the congress office:
MedConcept GmbH, Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany,
info@medconcept.org, Fax: +49 (0)3342 42689-30

Online-Registration:
https://postchicago2021.org/registration
SPONSORS

PLATINUM

- Bristol Myers Squibb
- MSD
- Novartis
- Regeneron
- Sanofi
- Genzyme

GOLD

- Immunocore
- Kyowa Kirin
- Pierre Fabre

BRONZE

- Philogen
- Roche

FURTHER SPONSORS

- 4SC
- Medac
- Sun Pharma

Platinum: 120,000 Euro / Gold: 90,000 Euro / Silver: 60,000 Euro / Bronze: 35,000 Euro
Realising the future together
How to achieve long-term outcomes for patients with advanced BRAF-mutant melanoma?

Thursday 8 July 2021, 09:30–10:30 CEST

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Facilitator</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30–09:35</td>
<td>Welcome and introductions</td>
<td>Axel Hauschild</td>
</tr>
<tr>
<td>09:35–09:45</td>
<td><strong>Our current understanding</strong> of the targeted therapy landscape in advanced BRAF-mutant melanoma (live session)</td>
<td>Axel Hauschild</td>
</tr>
<tr>
<td>09:45–10:00</td>
<td><strong>Clinical experience</strong> in achieving long-term outcomes for patients with advanced BRAF-mutant melanoma (case reviews)</td>
<td>Eva Muñoz, Mario Mandalà</td>
</tr>
<tr>
<td>10:00–10:10</td>
<td><strong>Clinical perspectives</strong> on patient outcomes (live session)</td>
<td>Georgina Long</td>
</tr>
<tr>
<td>10:10–10:25</td>
<td><strong>Panel discussion</strong>: Your questions answered (live session with audience Q&amp;A)</td>
<td>All Faculty, Moderated by Georgina Long &amp; Axel Hauschild</td>
</tr>
<tr>
<td>10:25–10:30</td>
<td>Closing remarks</td>
<td>Georgina Long</td>
</tr>
</tbody>
</table>

**Chairs**
- Georgina Long (Sydney, Australia)
- Eva Muñoz (Barcelona, Spain)
- Axel Hauschild (Kiel, Germany)
- Mario Mandalà (Perugia, Italy)

**Speakers**
- Georgina Long
- Eva Muñoz
- Axel Hauschild
- Mario Mandalà
The melanoma IO-treatment continuum: latest achievements and persistent challenges

11th European Post-Chicago Melanoma/Skin Cancer Meeting Industry-Sponsored Symposium

Thursday, 8th July 2021 from 11:30 to 13:00 CEST
Available on demand until Thursday, 30th September

Meeting Chair
Dirk Schadendorf, MD
Director & Chair
Department of Dermatology
Director, Comprehensive Cancer Center
University Hospital Essen
Germany

Speaker
James Larkin, PhD, FRCP, FMedSci
Consultant
The Royal Marsden Hospital
London, United Kingdom

Speaker
Peter Mohr, MD, PhD
Chief Physician and Head
Skin Cancer Center Buxtehude
Department of Dermatology
Elbe Kliniken
Buxtehude, Germany

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 min</td>
<td>Welcome And Introduction</td>
</tr>
<tr>
<td></td>
<td>Dirk Schadendorf</td>
</tr>
<tr>
<td>25 min</td>
<td>Long Term Outcome And Open Questions Under IO-Combination Therapy</td>
</tr>
<tr>
<td></td>
<td>James Larkin</td>
</tr>
<tr>
<td>5 min</td>
<td>Live Panel Discussion</td>
</tr>
<tr>
<td>15 min</td>
<td>What Can We Expect From New Combinations In The Future?</td>
</tr>
<tr>
<td></td>
<td>Peter Mohr</td>
</tr>
<tr>
<td>5 min</td>
<td>Live Panel Discussion</td>
</tr>
<tr>
<td>20 min</td>
<td>The (Un)Known About Therapeutic Sequencing</td>
</tr>
<tr>
<td></td>
<td>Dirk Schadendorf</td>
</tr>
<tr>
<td>5 min</td>
<td>Live Panel Discussion</td>
</tr>
<tr>
<td>10 min</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>

This industry-sponsored symposium is a medical education activity that is organized and funded by the medical department of Bristol Myers Squibb.
# Transforming Patient Care in Melanoma

**Virtual**

**Thursday, 8 July 2021**

**14:30 - 16:00 (CEST)**

**Chair:** Axel Hauschild (Germany)

## Educational objectives:
- Review current data in the adjuvant setting and understand ongoing unmet needs of high-risk melanoma patients
- Review the latest data updates in advanced melanoma and understand ongoing unmet needs in the metastatic melanoma setting
- Discuss data translation into clinical practice through patient cases and discuss evidence-based decision-making in the optimization of early and late melanoma patient management

## Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 14:35</td>
<td>Welcome and introductions</td>
<td>Axel Hauschild</td>
</tr>
<tr>
<td>14:35 - 14:50</td>
<td>Adjuvant treatment of high-risk melanoma</td>
<td>Olivier Michielin</td>
</tr>
<tr>
<td>14:50 - 15:10</td>
<td>Evolving landscape of adjuvant treatment for high-risk melanoma</td>
<td>Olivier Michielin</td>
</tr>
<tr>
<td>15:25 - 15:45</td>
<td>Combining data with clinical experience to optimize patient outcome with advanced melanoma</td>
<td>Hussein Tawbi</td>
</tr>
<tr>
<td>15:45 - 16:00</td>
<td>Q&amp;A/Panel discussion</td>
<td>All faculty</td>
</tr>
<tr>
<td></td>
<td>Closing remarks</td>
<td>Axel Hauschild</td>
</tr>
</tbody>
</table>

**Professor and Head, Dermato-Oncology Department, University of Kiel, Kiel, Germany**

**Consultant, The Royal Marsden Hospital, London, United Kingdom**

**Chief Physician and Head, Skin Cancer Center Buxtehude, Department of Dermatology, Elbe Kliniken, Buxtehude, Germany**

**Professor of Dermatology, Head of the Skin Cancer Center, Medical University of Vienna, Department of Dermatology, Vienna, Austria**

**Professor and Head, Center of Precision Medicine, Deputy Head of Immuno-Oncology Service, University Hospital, Lausanne, Switzerland**

**Distinguished Professorship in Surgical Oncology, Chief, Melanoma Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA**

**Professor and Deputy Chair, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA**
Dear Colleague,

I invite you to attend the virtual symposium titled Staying on Track: Evolving Considerations for Patient Management in Melanoma, being held during the 11th European Post-Chicago Melanoma/Skin Cancer Meeting.

During this symposium, we will discuss the current treatment landscape and remaining unmet needs in metastatic and adjuvant melanoma, as well as strategies for effective adverse event management to support long-term treatment benefits. We will also hear both clinician and patient perspectives on how melanoma management has been affected in the era of COVID-19.

We encourage live interaction with our panel of experts throughout the symposium. We look forward to you joining us!

Best regards,

Axel Hauschild, MD, PhD
University Hospital Schleswig-Holstein
Kiel, Germany

Dirk Schadendorf, MD
University Hospital Essen
Essen, Germany

Peter Mohr, MD
Skin Cancer Center Buxtehude
Buxtehude, Germany

Victoria Atkinson, MD
Princess Alexandra Hospital
Woolloongabba QLD, Australia

Katharina Kaminski (Patient Advocate)
Melanoma Info Deutschland
Berg, Germany

---

**Program**

10:30-10:35 CEST
Welcome From the Chair
Axel Hauschild

10:35-10:40 CEST
Current State of the Melanoma Landscape

10:40-10:50 CEST
Clinical Insights, Discussion and Q&A
Axel Hauschild, Dirk Schadendorf, and Peter Mohr

10:50-11:05 CEST
Strategies for Effective Adverse Event Management
Victoria Atkinson

11:05-11:15 CEST
Clinical Insights, Discussion and Q&A
Axel Hauschild, Dirk Schadendorf, and Peter Mohr

11:15-11:35 CEST
Considerations for Patient Management in the Time of COVID-19
Dirk Schadendorf and Katharina Kaminski

11:35-11:45 CEST
Clinical Insights, Discussion and Q&A
Axel Hauschild, Dirk Schadendorf, and Peter Mohr

11:45-12:00 CEST
General Discussion and Q&A
Axel Hauschild, Dirk Schadendorf, and Peter Mohr

---

This program is supported by Novartis. This program is intended for non-US physicians.
Dear Colleague,

I invite you to attend the virtual symposium titled "Staying on Track: Evolving Considerations for Patient Management in Melanoma," being held during the 11th European Post-Chicago Melanoma/Skin Cancer Meeting.

During this symposium, we will discuss the current treatment landscape and remaining unmet needs in metastatic and adjuvant melanoma, as well as strategies for effective adverse event management to support long-term treatment benefits. We will also hear both clinician and patient perspectives on how melanoma management has been affected in the era of COVID-19.

We encourage live interaction with our panel of experts throughout the symposium. We look forward to you joining us!

Best regards,

Axel Hauschild, MD, PhD
University Hospital Schleswig-Holstein
Kiel, Germany

Dirk Schadendorf, MD
University Hospital Essen
Essen, Germany

Katharina Kaminski (Patient Advocate)
Melanoma Info Deutschland
Berg, Germany

Victoria Atkinson, MD
Princess Alexandra Hospital
Woolloongabba QLD, Australia

Speakers
Peter Mohr, MD
Skin Cancer Center Buxtehude
Buxtehude, Germany